Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)
JMIR Cancer · 2025
DOI: 10.2196/65960 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JMIR Cancer, 2025. Verfasst von Katell Le Dû und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Confluent Private Hospital, 2 rue Eric Tabarly, Nantes, 44277, France, 33 0615246067. Hauptthemen laut MEDLINE: Lymphoma, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Relapse is a major event in patients with lymphoma. Therefore, early detection may have an impact on quality of life and overall survival. Patient-reported outcome measures have demonstrated clinical benefits for patients with lung cancer; however, evidence is lacking in patients with lymphoma. We evaluated the effect of a web-mediated follow-up application for patients with lymphoma at high risk of relapse.
Objective
This study aims to demonstrate that monitoring patients via a web application enables the detection of at least 30% more significant events occurring between 2 systematic follow-up consultations with the specialist using an electronic questionnaire.
Methods
We conducted a prospective, randomized phase 3 trial comparing the impact of web-based follow-up (experimental arm) with a standard follow-up (control arm). The trial was based on a 2-step triangular test and was designed to have a power of 90% to detect a 30% improvement in the detection of significant events. A significant event was defined as a relapse, progression, or a serious adverse event. The study covered the follow-up period after completion of first-line treatment or relapse (24 months). Eligible patients were aged 18 years and older and had lymphoma at a high risk of relapse. In the experimental arm, patients received a 16-symptom questionnaire by email every 2 weeks. An email alert was sent to the medical team based on a predefined algorithm. The primary objective was assessed after the inclusion of the 40th patient. The study was continued for the duration of the analysis.
Results
A total of 52 patients were included between July 12, 2017, and April 7, 2020, at 11 centers in France, with 27 in the experimental arm and 25 in the control arm. The median follow-up was 21.3 (range 1.3‐25.6) months, and 121 events were reported during the study period. Most events occurred in the experimental arm (83/119, 69.7%) compared with 30.2% (36/119) in the control arm. A median number of 3.5 (range 1-8) events per patient occurred in the experimental arm, and 1.8 (range 1-6) occurred in the control arm ( P =.01). Progression and infection were the most frequently reported events. Further, 19 patients relapsed during follow-up: 6 in the experimental arm and 13 in the control arm ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Confluent Private Hospital, 2 rue Eric Tabarly, Nantes, 44277, France, 33 0615246067.
- Department of Hematology, University Hospital, Besançon, France.
- Department of Hematology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
- Department of Hematology, Bergonié Institute, Bordeaux, France.
- Department of Hematology, Mont de Marsan Hospital, Mont de Marsan, France.
- Department of Hematology, Clinique Saint-Anne, Strasbourg, France.
ORCID-Profile: Katell Le Dû, Adrien Chauchet, Sophie Sadot-Lebouvier, Olivier Fitoussi, Bijou Fontanet, Arnaud Saint-Lezer, Frédéric Maloisel, Cédric Rossi, Sylvain Carras, Anne Parcelier, Magali Balavoine, Anne-Lise Septans
Zitieren
APA
Le Dû, K., Chauchet, A., Sadot-Lebouvier, S., Fitoussi, O., Fontanet, B., Saint-Lezer, A., Maloisel, F., Rossi, C., Carras, S., Parcelier, A., Balavoine, M., & Septans, A. L. (2025). Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). JMIR Cancer. https://doi.org/10.2196/65960
Vancouver
Le Dû K, Chauchet A, Sadot-Lebouvier S, Fitoussi O, Fontanet B, Saint-Lezer A, et al. Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma). JMIR Cancer. 2025. doi:10.2196/65960
BibTeX
@article{LeD2025,
author = {Le Dû, Katell and Chauchet, Adrien and Sadot-Lebouvier, Sophie and Fitoussi, Olivier and Fontanet, Bijou and Saint-Lezer, Arnaud and Maloisel, Frédéric and Rossi, Cédric and Carras, Sylvain and Parcelier, Anne and Balavoine, Magali and Septans, Anne-Lise},
title = {Comparison of Electronic Surveillance With Routine Monitoring for Patients With Lymphoma at High Risk of Relapse: Prospective Randomized Controlled Phase 3 Trial (Sentinel Lymphoma)},
journal = {JMIR Cancer},
year = {2025},
doi = {10.2196/65960}
}
EUVIMED